Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 13/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | UQCRB | P14927 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973876 | 0.84 | CCR9 (0.48) | CCR9HSD17B2GLO1PIK3CDUQCRB | |
| SCHEMBL2975323 | 0.84 | CCR9 (0.48) | CCR9HSD17B2PIK3CDUQCRBTP53 | |
| SCHEMBL2981244 | 0.83 | PIK3CD (0.49) | CCR9HSD17B2PIK3CD | |
| SCHEMBL2971727 | 0.81 | CCR9 (0.50) | CCR9HSD17B2 | |
| SCHEMBL2970021 | 0.81 | HSD17B2 (0.53) | CCR9HSD17B2UQCRB | |
| SCHEMBL2976044 | 0.81 | CCR9 (0.51) | CCR9HSD17B2GLO1UQCRB | |
| SCHEMBL2978871 | 0.81 | CCR9 (0.48) | CCR9HSD17B2PIK3CDTP53GAA | |
| SCHEMBL2977421 | 0.80 | HSD17B2 (0.49) | CCR9HSD17B2PIK3CD | |
| SCHEMBL2981274 | 0.80 | CCR9 (0.47) | CCR9HSD17B2PIK3CDUQCRB | |
| SCHEMBL2978947 | 0.78 | CCR9 (0.48) | CCR9HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409909-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | claimed |
| EP-2170823-B1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES | CHEMOCENTRYX INC (US) | 2014-08-06 | — | — | EP | claimed |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-09-27 | — | — | US | claimed |
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-12-30 | — | — | US | claimed |
| EP-2170823-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES | ChemoCentryx Inc (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009038847-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | claimed |
| US-9409909-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409909-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409909-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-7776877-B2 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2170823-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES | ChemoCentryx Inc (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009038847-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | CCR9 1/4885HSD17B2 1177/4885GLO1 3675/4885 |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | CCR9 1/4885HSD17B2 1177/4885GLO1 3675/4885 |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CCR9, CCR1, CCR2 | CCR9 1/4885HSD17B2 3385/4885GLO1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.